Paopat Munthananuchat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paopat Munthananuchat has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Akeatit Trirattanapikul
Mahidol University Faculty of Medicine Ramathibodi Hospital
2 shared publicationsBundit Naratreekoon
Mahidol University Faculty of Medicine Ramathibodi Hospital
2 shared publicationsNarongrit Kantathut
Mahidol University Faculty of Medicine Ramathibodi Hospital
2 shared publications- Piya Samankatiwat
Division of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2 shared publications - Pintip Ngamjanyaporn
Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
1 shared publication - Porpon Rotjanapan
Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
1 shared publication
Latest Publications
- Open Access
- 29 April 2024
- Published by Wiley
Overcoming Double Jeopardy: Successful Orthotopic Heart Transplant in a Recipient with Bacterial and Fungal Infections
Introduction Heart transplantation is considered an important treatment option for advance heart failure patient who do not respond to medical therapy. However, before surgery, contraindications for heart transplantation should be evaluated. These contraindications may include fixed pulmonary hypertension, active cancer, HIV infection, or active infections with unstable conditions. [1]Infection is a significant concern for patients undergoing heart transplantation include pre- and post-operative period, as it may lead to the risk of severe infections in these patients. In fact, infections are the second leading cause of death after graft rejection within the first 30 days following heart transplantation and the leading cause of death beyond 30 days post transplantation. [2,3] Bacterial infections are significant concern for patients undergoing heart transplantation. According to a study, the incidence of bacterial infections in these patients can be as high as 43.6%. Common causes of infection include pneumonia, bloodstream infections due to the placement of central venous catheters, and infections associated with the use of ventricular assist devices. In the past, the mortality rate from invasive pulmonary aspergillosis in heart transplant patients was as high as 66.7%. However, advancements in medical treatments, including antifungal medications, adjustment of immunosuppressive therapy, and improved surgical techniques, have improve survival in these patients. [4,5] As a result, current medical guidelines recommend treating fungal infections until symptoms, radiological findings, and laboratory tests show improvement before proceeding with heart transplantation. However, there are no specific recommendations for the optimal duration of treatment before emergency heart transplantation or in cases where the patient’s condition requires urgent surgery. [6]
- 29 April 2024
- Published by Wiley
Open AccessOvercoming Double Jeopardy: Successful Orthotopic Heart Transplant in a Recipient with Bacterial and Fungal Infections
Introduction Heart transplantation is considered an important treatment option for advance heart failure patient who do not respond to medical therapy. However, before surgery, contraindications for heart transplantation should be evaluated. These contraindications may include fixed pulmonary hypertension, active cancer, HIV infection, or active infections with unstable conditions. [1]Infection is a significant concern for patients undergoing heart transplantation include pre- and post-operative period, as it may lead to the risk of severe infections in these patients. In fact, infections are the second leading cause of death after graft rejection within the first 30 days following heart transplantation and the leading cause of death beyond 30 days post transplantation. [2,3] Bacterial infections are significant concern for patients undergoing heart transplantation. According to a study, the incidence of bacterial infections in these patients can be as high as 43.6%. Common causes of infection include pneumonia, bloodstream infections due to the placement of central venous catheters, and infections associated with the use of ventricular assist devices. In the past, the mortality rate from invasive pulmonary aspergillosis in heart transplant patients was as high as 66.7%. However, advancements in medical treatments, including antifungal medications, adjustment of immunosuppressive therapy, and improved surgical techniques, have improve survival in these patients. [4,5] As a result, current medical guidelines recommend treating fungal infections until symptoms, radiological findings, and laboratory tests show improvement before proceeding with heart transplantation. However, there are no specific recommendations for the optimal duration of treatment before emergency heart transplantation or in cases where the patient’s condition requires urgent surgery. [6]
- Open Access
- 1 January 2024
- Published by Wiley in Case Reports in Cardiology
- Vol. 2024 (1)
Overcoming Double Jeopardy: Successful Orthotopic Heart Transplant in a Recipient With Bacterial and Fungal Infections
Although active infection is generally a contraindication before an orthotopic heart transplant, a 16‐year‐old man diagnosed with dilated cardiomyopathy successfully underwent an orthotopic heart transplant despite having active probable invasive pulmonary aspergillosis and bacterial pneumonia in the presence of septic and cardiogenic shock.
- 1 January 2024
- Published by Wiley in Case Reports in Cardiology
- Vol. 2024 (1)
Open AccessOvercoming Double Jeopardy: Successful Orthotopic Heart Transplant in a Recipient With Bacterial and Fungal Infections
Although active infection is generally a contraindication before an orthotopic heart transplant, a 16‐year‐old man diagnosed with dilated cardiomyopathy successfully underwent an orthotopic heart transplant despite having active probable invasive pulmonary aspergillosis and bacterial pneumonia in the presence of septic and cardiogenic shock.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2222. A study of the role of trimethoprim-sulfamethoxazole in opportunistic infection prevention in lupus patients taking low-level immunosuppressive treatment: An open-labeled, randomized controlled trial
Individuals with lupus are at risk of opportunistic infections (OIs), especially pneumocystis pneumonia and nocardiosis. The current recommendation to prevent OIs is to take trimethoprim-sulfamethoxazole (TMP/SMX) regularly while on treatment for lupus. However, there has yet to be a standard recommendation on whether TMP/SMX prophylaxis is necessary and when prophylaxis can be discontinued. To assess the role of TMP/SMX in primary prophylaxis of OIs and to study the incidence of TMP/SMX sensitive OIs and the adverse events of TMP/SMX in the real-world setting among lupus patients taking low-level immunosuppressive therapy. An open-label, randomized controlled trial was conducted among lupus patients taking low-level immunosuppressive at Ramathibodi Hospital between May 2021 and April 2023. The patient's demographic and relevant data were retrieved. The patients were randomized to receive or not receive TMP/SMX in a 1:1 ratio. The dose of TMP/SMX was adjusted based on renal function. The incidence of TMP/SMX-sensitive OIs was monitored until one year from enrollment, and the adverse events were assessed. The study was terminated prematurely due to an exceedingly high rate of adverse events secondary to TMP/SMX use. The analysis was made for the enrolled 138 lupus patients at six months, and OIs were monitored until one year. The mean ages were 45.4 in both groups. Most patients (98.4%) had SLEDAI-2K score < 4. The doses of immunosuppressive therapy were adjusted in six patients due to active disease and therefore excluded from the study. No TMP/SMX sensitive OIs documented in 114 lupus patients who completed follow-ups over nine months since enrollment. Eight from 10 patients had grade 1, whereas 2/10 patients had grade 3 adverse drug reactions, and all declined to resume prophylaxis. There was no mortality in the study. The incidence of TMP/SMX-sensitive OIs among lupus patients taking low-level immunosuppressive was not a significant concern after a one-year follow-up, and high rates of adverse events with TMP/SMX prophylaxis were documented. Therefore, TMP/SMX primary prophylaxis may not be justified in this population. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2222. A study of the role of trimethoprim-sulfamethoxazole in opportunistic infection prevention in lupus patients taking low-level immunosuppressive treatment: An open-labeled, randomized controlled trial
Individuals with lupus are at risk of opportunistic infections (OIs), especially pneumocystis pneumonia and nocardiosis. The current recommendation to prevent OIs is to take trimethoprim-sulfamethoxazole (TMP/SMX) regularly while on treatment for lupus. However, there has yet to be a standard recommendation on whether TMP/SMX prophylaxis is necessary and when prophylaxis can be discontinued. To assess the role of TMP/SMX in primary prophylaxis of OIs and to study the incidence of TMP/SMX sensitive OIs and the adverse events of TMP/SMX in the real-world setting among lupus patients taking low-level immunosuppressive therapy. An open-label, randomized controlled trial was conducted among lupus patients taking low-level immunosuppressive at Ramathibodi Hospital between May 2021 and April 2023. The patient's demographic and relevant data were retrieved. The patients were randomized to receive or not receive TMP/SMX in a 1:1 ratio. The dose of TMP/SMX was adjusted based on renal function. The incidence of TMP/SMX-sensitive OIs was monitored until one year from enrollment, and the adverse events were assessed. The study was terminated prematurely due to an exceedingly high rate of adverse events secondary to TMP/SMX use. The analysis was made for the enrolled 138 lupus patients at six months, and OIs were monitored until one year. The mean ages were 45.4 in both groups. Most patients (98.4%) had SLEDAI-2K score < 4. The doses of immunosuppressive therapy were adjusted in six patients due to active disease and therefore excluded from the study. No TMP/SMX sensitive OIs documented in 114 lupus patients who completed follow-ups over nine months since enrollment. Eight from 10 patients had grade 1, whereas 2/10 patients had grade 3 adverse drug reactions, and all declined to resume prophylaxis. There was no mortality in the study. The incidence of TMP/SMX-sensitive OIs among lupus patients taking low-level immunosuppressive was not a significant concern after a one-year follow-up, and high rates of adverse events with TMP/SMX prophylaxis were documented. Therefore, TMP/SMX primary prophylaxis may not be justified in this population. All Authors: No reported disclosures